FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362525361> ?p ?o ?g. }

• W4362525361 abstract "<div><p>Recombinant human high-dose IL2 (HD-IL2; aldesleukin) was one of the first approved immune-oncology agents based upon clinical activity in renal cell carcinoma (RCC) and metastatic melanoma but use was limited due to severe toxicity. Next-generation IL2 agents designed to improve tolerability are in development, increasing the need for future identification of genomic markers of clinical benefit and/or clinical response. In this retrospective study, we report clinical and tumor molecular profiling from patients with metastatic RCC (mRCC) treated with HD-IL2 and compare findings with patients with RCC treated with anti-PD-1 therapy. Genomic characteristics common and unique to IL2 and/or anti-PD-1 therapy response are presented, with insight into rational combination strategies for these agents.</p><p>Residual pretreatment formalin-fixed paraffin embedded tumor samples from <i>n</i> = 36 patients with HD-IL2 mRCC underwent RNA-sequencing and corresponding clinical data were collected. A <i>de novo</i> 40-gene nearest centroid IL2 treatment response classifier and individual gene and/or immune marker signature differences were correlated to clinical response and placed into context with a separate dataset of <i>n</i> = 35 patients with anti-PD-1 mRCC.</p><p>Immune signatures and genes, comprising suppressor and effector cells, were increased in patients with HD-IL2 clinical benefit. The 40-gene response classifier was also highly enriched for immune genes. While several effector immune signatures and genes were common between IL2 and anti-PD-1 treated patients, multiple inflammatory and/or immunosuppressive genes, previously reported to predict poor response to anti-PD-L1 immunotherapy, were only increased in IL2–responsive tumors.</p><p>These findings suggest that common and distinct immune-related response markers for IL2 and anti-PD-1 therapy may help guide their use, either alone or in combination.</p>Significance:<p>Next-generation IL2 agents, designed for improved tolerability over traditional HD-IL2 (aldesleukin), are in clinical development. Retrospective molecular tumor profiling of patients treated with HD-IL2 or anti-PD-1 therapy provides insights into genomic characteristics of therapy response. This study revealed common and distinct immune-related predictive response markers for IL2 and anti-PD-1 therapy which may play a role in therapy guidance, and rational combination strategies for these agents.</p></div>" @default.
• W4362525361 created "2023-04-06" @default.
• W4362525361 creator A5000114315 @default.
• W4362525361 creator A5006119803 @default.
• W4362525361 creator A5015001132 @default.
• W4362525361 creator A5029557897 @default.
• W4362525361 creator A5032081996 @default.
• W4362525361 creator A5039246179 @default.
• W4362525361 creator A5045513996 @default.
• W4362525361 creator A5051183306 @default.
• W4362525361 creator A5051892780 @default.
• W4362525361 creator A5069373371 @default.
• W4362525361 creator A5072462794 @default.
• W4362525361 creator A5086264516 @default.
• W4362525361 creator A5088232810 @default.
• W4362525361 creator A5088315368 @default.
• W4362525361 date "2023-04-04" @default.
• W4362525361 modified "2023-09-23" @default.
• W4362525361 title "Data from Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer" @default.
• W4362525361 doi "https://doi.org/10.1158/2767-9764.c.6550872" @default.
• W4362525361 hasPublicationYear "2023" @default.
• W4362525361 type Work @default.
• W4362525361 citedByCount "0" @default.
• W4362525361 crossrefType "posted-content" @default.
• W4362525361 hasAuthorship W4362525361A5000114315 @default.
• W4362525361 hasAuthorship W4362525361A5006119803 @default.
• W4362525361 hasAuthorship W4362525361A5015001132 @default.
• W4362525361 hasAuthorship W4362525361A5029557897 @default.
• W4362525361 hasAuthorship W4362525361A5032081996 @default.
• W4362525361 hasAuthorship W4362525361A5039246179 @default.
• W4362525361 hasAuthorship W4362525361A5045513996 @default.
• W4362525361 hasAuthorship W4362525361A5051183306 @default.
• W4362525361 hasAuthorship W4362525361A5051892780 @default.
• W4362525361 hasAuthorship W4362525361A5069373371 @default.
• W4362525361 hasAuthorship W4362525361A5072462794 @default.
• W4362525361 hasAuthorship W4362525361A5086264516 @default.
• W4362525361 hasAuthorship W4362525361A5088232810 @default.
• W4362525361 hasAuthorship W4362525361A5088315368 @default.
• W4362525361 hasConcept C126322002 @default.
• W4362525361 hasConcept C143998085 @default.
• W4362525361 hasConcept C203014093 @default.
• W4362525361 hasConcept C2777472916 @default.
• W4362525361 hasConcept C502942594 @default.
• W4362525361 hasConcept C71924100 @default.
• W4362525361 hasConcept C8891405 @default.
• W4362525361 hasConceptScore W4362525361C126322002 @default.
• W4362525361 hasConceptScore W4362525361C143998085 @default.
• W4362525361 hasConceptScore W4362525361C203014093 @default.
• W4362525361 hasConceptScore W4362525361C2777472916 @default.
• W4362525361 hasConceptScore W4362525361C502942594 @default.
• W4362525361 hasConceptScore W4362525361C71924100 @default.
• W4362525361 hasConceptScore W4362525361C8891405 @default.
• W4362525361 hasLocation W43625253611 @default.
• W4362525361 hasOpenAccess W4362525361 @default.
• W4362525361 hasPrimaryLocation W43625253611 @default.
• W4362525361 hasRelatedWork W1994903659 @default.
• W4362525361 hasRelatedWork W1997169225 @default.
• W4362525361 hasRelatedWork W2005149537 @default.
• W4362525361 hasRelatedWork W2045737731 @default.
• W4362525361 hasRelatedWork W2096517981 @default.
• W4362525361 hasRelatedWork W2360810719 @default.
• W4362525361 hasRelatedWork W2362434115 @default.
• W4362525361 hasRelatedWork W2436311630 @default.
• W4362525361 hasRelatedWork W2790557737 @default.
• W4362525361 hasRelatedWork W2968450929 @default.
• W4362525361 isParatext "false" @default.
• W4362525361 isRetracted "false" @default.
• W4362525361 workType "article" @default.